Despite universally elevated levels due to impaired kidney clearance, natriuretic peptides (BNP, NT-proBNP) still show moderate-to-strong associations with cardiac disease and mortality in end-stage kidney disease patients.
Moderate-to-strongcorrelation between natriuretic peptides and cardiac outcomes in ESKD, despite elevated baselines
What the researchers found
Serum natriuretic peptide concentrations in ESKD patients show moderate to strong positive relationships with underlying heart disease, abnormal cardiac structure/function, and mortality, despite universally elevated baseline levels due to impaired renal clearance.
Why it matters
Cardiovascular disease is the leading cause of death in dialysis patients. Having reliable biomarkers to assess cardiac risk in this population could guide treatment decisions and improve outcomes — but clinicians need to know how to interpret elevated NP levels in the context of kidney failure.
The numbers in context
NP levels universally elevated in ESKD; still prognostic for CV events and mortality.
How the study worked
Narrative review of published literature on natriuretic peptide pathophysiology, clinical significance, and risk stratification utility in end-stage kidney disease patients.
Who was studied
Patients with end-stage kidney disease across multiple observational studies
What this study cannot tell us
Narrative review format without systematic methodology. Inconsistent cutoff values across studies prevent definitive clinical recommendations. Limited data on some NP subtypes (CNP, DNP) in ESKD.
How to read the evidence
Narrative review synthesizing observational and clinical evidence. Consistent direction of findings but inconsistent quantitative cutoffs limit definitive recommendations.
When this study was published
Published in 2020. Natriuretic peptide use in kidney disease continues to be refined with larger studies.
The bigger picture
As the kidney disease population grows globally, tools for cardiovascular risk assessment in these patients become increasingly important. This review provides clinicians with a framework for interpreting natriuretic peptide levels despite the confounding effect of impaired renal clearance.
Questions still open
- What are the optimal NP cutoff values for cardiac risk stratification in ESKD patients?
- Should NP monitoring be routinely incorporated into dialysis patient care?
- How do NP levels change in response to treatment optimization in ESKD patients?
Common questions
Why are natriuretic peptide levels always high in kidney disease patients?
What are natriuretic peptides?
Read the original research
Pathophysiology and significance of natriuretic peptides in patients with end-stage kidney disease.
Clinical biochemistry, 83, 1-11
Citation
Yang, Wen-Ling; Fahim, Magid; Johnson, David W. (2020). Pathophysiology and significance of natriuretic peptides in patients with end-stage kidney disease.. Clinical biochemistry, 83, 1-11. https://doi.org/10.1016/j.clinbiochem.2020.05.013